Artículos originalesTratamiento de las epistaxis en la telangiectasia hemorrágica hereditaria (enfermedad de Rendu-Osler-Weber) con ácido tranexámicoTreatment of Epistaxes in Hereditary Haemorrhagic Telangiectasia (Rendu-Osler-Weber Disease) With Tranexamic Acid
Bibliografía (29)
- et al.
Telangiectasia hemorrágica hereditaria
Med Clin (Barc)
(2005) - et al.
El tratamiento local esclerosante con etoxiesclerol en la patología ORL: enfermedad de Rendu-Osler, granulomas, angiomas
Acta Otorrinolaringol Esp
(2002) - et al.
Hereditary hemorrhagic telangiectasia response to aminocaproic acid treatment
Thromb Res
(1999) - et al.
Eficacia del ácido tranexámico en un pacientes con THH y epistaxis masiva
Med Clin(Barc)
(2004) - et al.
Plasma surgery and topical estriol: effects on the nasal mucosa and long-term reults in patients with Osler's disease
Otolaryngol Head Neck Surg
(2003) Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation: influence of omega-aminocarboxylic acids
Biochim Biophys Acta
(1975)- et al.
Studies on the mechanism of the antifibrinolytic action of tranexamic acid
Biochim Biophys Acta
(1981) - et al.
La enfermedad de Rendu-Osler-Weber (telangiectasia hemorrágica hereditaria). Presentación de 30 casos
Acta Otorrinolaringol Esp
(1997) - et al.
Endoglin, a TGF-B binding protein of endothelial cells, is the gene fo hereditary haemorrhagic telangiectasia type 1
Nat Genet
(1994) - et al.
Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2
Nat Genet
(1996)
A new locus for hereditary haemorhagic telangiectasia (HHT3) maps to chromosome 5
J Med Genet
Age related profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population
Am J Med Genet
Hereditary hemorrhagic telangiectasia
Otolaryngol Head Neck Surg
The natural history of epistaxis in hereditary hemorrhagic telangiectasia
Laryngoscope
Cited by (22)
North American Study for the Treatment of Recurrent Epistaxis with Doxycycline: The NOSTRIL trial
2022, Journal of Thrombosis and HaemostasisIntravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia–Related Epistaxis and Gastrointestinal Bleeding
2018, Mayo Clinic ProceedingsCitation Excerpt :In contrast, severe HHT-related epistaxis is a difficult and frustrating entity with few treatment options that provide durable long-term relief from rebleeding. A stepwise approach13,14 has been suggested, with various oral and interventional therapies to be attempted in an escalating fashion, including oral aminocaproic acid,15 danazol,16 tranexamic acid,17-19 selective estrogen receptor modifiers,20,21 oral contraceptive pills,16,21-23 sclerotherapy,24-26 laser and bipolar cauterization,27-31 selective arterial embolization,32-38 septodermoplasty,39-41 and nasal closure (Young's procedure).14,42-45 All patients in our study had received and failed 1 or more of these therapies (except nasal closure) on a number of occasions before the initiation of IV bevacizumab.
Hereditary hemorrhagic telangiectasia: Rendu-Osler-Weber disease
2016, FMC Formacion Medica Continuada en Atencion PrimariaTreatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - A double-blind placebo-controlled cross-over phase IIIB study
2014, Thrombosis ResearchCitation Excerpt :Several pharmaceutical approaches have been discussed, including hormonal therapies, anti-VEGF-antibodies and antifibrinolytics. A number of promising case reports and series have been published about the efficacy of tranexamic acid and epsilon-aminocaproic acid in HHT [3–5]. The rationale for using antifibrinolytics is not fully understood.
Hereditary hemorrhagic telangiectasia: An overview of diagnosis, management, and pathogenesis
2011, Genetics in Medicine